Gilead Sciences, Inc. (BCBA:GILD)

Market Cap	223.02T
Revenue (ttm)	39.86T
Net Income (ttm)	11.11T
Shares Out	n/a
EPS (ttm)	8,802.50
PE Ratio	20.07
Forward PE	14.84
Dividend	746.32 (1.57%)
Ex-Dividend Date	Dec 15, 2025

Volume	280
Average Volume	247
Open	47,980
Previous Close	47,500
Day's Range	47,340 - 47,980
52-Week Range	25,150 - 50,000
Beta	n/a
RSI	50.22
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD